Randomised Controlled Trial to study differences in health-related quality of life in curative intended prostate cancer patients after randomising androgen receptor inhibitor monotherapy versus castration plus an androgen receptor inhibitor.
Mainly intermediate-risk group of prostate cancer patients were included at Radiumhemmet, Karolinska Univeristy Hospital, Sweden with a ratio of 1:1.
Two European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaires were used (EORTC QLQ C-30 + EORTC QLQ PR25).
Better sexual interset was noted in patients treated with androgen receptor inhibitor monotherapy compared to castration plus an androgen receptor inhibitor at 3 and 18-month follow-up assessments.
Study was not powered enough to address on overall survival due to relatively small sample size and shorter follow-up time.